Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(-) chronic hepatitis B patients (Study ETV-027)

被引：0
|
作者：
Lai, Ching-Lung
Chang, Ting-Tsung
Chao, You-Chen
Tanwandee, Tawesak
Thongsawat, Satawat
Lee, Shou-Dong
Angus, Peter
Zink, Richard
Zhu, Jin
Brett-Smith, Helena
Neo, Boon-Leong
机构：
[1] Queen Mary Hosp, Hong Kong 70101, Peoples R China
[2] Natl Cheng Kung Univ, Coll Med, Tainan, Taiwan
[3] Tri Serv Gen Hosp, Taipei 10700, Taiwan
[4] Mahidol Univ, Siriraj Hosp, Bangkok, Thailand
[5] Maharajnakorn Chiang Mai Hosp, Chiang Mai, Thailand
[6] Taipei Vet Gen Hosp, Taipei, Taiwan
[7] Austin & Repatriation Med Ctr, West Heidelbrg, Vic, Australia
[8] Bristol Myers Squibb Pharmaceut Res Inst, Wallingford, CT USA
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2006年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A128 / A128
页数：1
相关论文
共 50 条
  • [31] Efficacy of 96 weeks adefovir dipivoxil treatment in HBeAg positive chronic hepatitis B patients with various baseline biochemical levels
    Zhuang, L.
    You, J.
    Kong, L.
    Lei, H.
    Yang, R. -D
    Zhang, X.
    Wang, Q. -Q
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2010, 14 : E236 - E237
  • [32] Treatment efficacy of switching to tenofovir strategy over continued entecavir therapy in chronic hepatitis B patients with partial virologic response to entecavir
    Lee, Jun Seob
    Jang, Byoung Kuk
    Kwon, Sang Hoon
    Yoon, Jun Sik
    Kim, Hyeong Seok
    Lee, Yu Rim
    Kweon, Young-Oh
    Tak, Won Young
    Park, Soo Young
    Jang, Se Young
    Wang, ShanShan
    Hur, Keun
    Lee, Eun Hye
    Jung, Da Yeon
    Kim, Gyeonghwa
    Choi, YongHun
    Park, Jung Gil
    Lee, Heon Ju
    Woo, Hyun Young
    Heo, Jeong
    HEPATOLOGY, 2016, 64 : 943A - 943A
  • [33] Efficacy of entecavir treatment for up to 96 weeks in nucleoside-naive HBeAg-positive chronic hepatitis B patients with high viral load
    Yan, Li-Bo
    Chen, En-Qiang
    Bai, Lang
    Du, Ling-Yao
    Chen, Lan-Lan
    Liao, Juan
    He, Min
    Tang, Hong
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2015, 39 (03) : 366 - 372
  • [34] Pretreatment HBeAg level and an early decrease in HBeAg level predict virologic response to entecavir treatment for HBeAg-positive chronic hepatitis B
    Kwon, J. H.
    Jang, J. W.
    Lee, S.
    Lee, J.
    Chung, K. W.
    Lee, Y. S.
    Choi, J. Y.
    JOURNAL OF VIRAL HEPATITIS, 2012, 19 (02) : E41 - E47
  • [35] Prospective randomized trial of switching to entecavir (ETV) in chronic hepatitis B Patients with suboptimal virologic response to lamivudine (LVD): interim analysis at 48 weeks
    Ahn, S. H.
    Park, J. Y.
    Lee, H-J
    Tak, W. Y.
    Um, S. H.
    Kim, D. Y.
    Yoon, K. T.
    Park, S. Y.
    Seo, Y. S.
    Han, K-H
    Cho, M.
    Heo, J.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 : A177 - A177
  • [36] A Comparison of the Efficacy and Safety of Entecavir Versus Lamivudine Through 240 Weeks of Treatment in Korean Patients with HBeAg-negative Chronic Hepatitis B
    Lee, Kwan Sik
    Kweon, Young-Oh
    Um, Soon Ho
    Kim, Byung-Ho
    Lim, Young Suk
    Paik, Seung Woon
    Heo, Jeong
    Lee, Heon Ju
    Kim, Dong Joon
    Kim, Tae Hun
    Lee, Young Sok
    Byun, Kwan Soo
    Kim, Dae-Ghon
    Lee, Myung Seok
    Llamoso, Cyril
    Yu, Kyungha
    Suh, Dong Jin
    HEPATOLOGY, 2014, 60 : 1119A - 1120A
  • [37] Entecavir maintained virologic suppression through 3 years of treatment in antiviral-naive HBeAg(+) patients (ETV 022/901)
    Chang, Ting-Tsung
    Chao, You-Chen
    Kaymakoglu, Sabahattin
    Cheinquer, Hugo
    Pessoa, Mario
    Gish, Robert
    Poordad, Fred
    Yang, Joanna
    Brett-Smith, Helena
    Hindes, Robert
    HEPATOLOGY, 2006, 44 (04) : 229A - 229A
  • [38] Entecavir is superior to lamivudine for the treatment of HBeAg(+) chronic hepatitis B: results of Phase III study ETV-022 in nucleoside-naive patients
    Chang, TT
    Gish, R
    de Man, R
    Gadano, A
    Sollano, J
    Han, KH
    Goodman, Z
    Zhu, J
    Cross, A
    DeHertogh, D
    Apelian, D
    ANTIVIRAL THERAPY, 2004, 9 (06) : H21 - H22
  • [39] Entecavir is superior to lamivudine for the treatment of HBeAg(+) chronic hepatitis B: Results of phase III study ETV-022 in nucleoside-naive patients
    Chang, TT
    Gish, R
    de Man, R
    Gadano, A
    Sollano, J
    Han, KH
    Goodman, Z
    Zhu, J
    Cross, A
    Dehertogh, D
    Apelian, D
    HEPATOLOGY, 2004, 40 (04) : 193A - 193A
  • [40] ENTECAVIR (ETV) MONOTHERAPY FOR 96 WEEKS IS COMPARABLE TO COMBINATION THERAPY WITH ETV PLUS TENOFOVIR (TDF) IN NUCLEOS(T)IDE-NAiVE PATIENTS WITH CHRONIC HEPATITIS B (CHB): THE BELOW STUDY
    Lok, Anna S.
    Trinh, Huy N.
    Carosi, Giampiero
    Akarca, Ulus S.
    Gadano, Adrian
    Habersetzer, Francois
    Sievert, William
    Wong, David K.
    Lovegren, Meghan
    Zhang, Hui
    Llamoso, Cyril
    HEPATOLOGY, 2011, 54 : 471A - 471A
12345